Prognostic significance of BRCA1-associated protein 1 in colorectal cancer

详细信息    查看全文

• 作者：Jianjun Tang (1)
  Shaoyan Xi (2)
  Gang Wang (1)
  Boqing Wang (1) (4)
  Shumei Yan (2)
  Yuanzhong Wu (1)
  Yi Sang (1)
  Wenjing Wu (1) (3)
  Ruhua Zhang (1)
  Tiebang Kang (1)
  
• 关键词：BRCA1 ; associated protein 1 ; BAP1 ; Colorectal cancer ; Prognosis
• 刊名：Medical Oncology
• 出版年：2013
• 出版时间：June 2013
• 年：2013
• 卷：30
• 期：2
• 全文大小：759KB
• 参考文献：1. Mayo SC, Pawlik TM. Current management of colorectal hepatic metastasis. Expert Rev Gastroenterol Hepatol. 2009;3(2):131-4. doi:10.1586/egh.09.8 . CrossRef
  2. Duffy MJ, van Dalen A, Haglund C, Hansson L, Holinski-Feder E, Klapdor R, Lamerz R, Peltomaki P, Sturgeon C, Topolcan O. Tumour markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines for clinical use. Eur J Cancer. 2007;43(9):1348-0. doi:10.1016/j.ejca.2007.03.021 . CrossRef
  3. Jia Y, Guo M. Epigenetic changes in colorectal cancer. Chin J Cancer. 2013;32(1):21-0. doi:10.5732/cjc.011.10245 . CrossRef
  4. Ventii KH, Devi NS, Friedrich KL, Chernova TA, Tighiouart M, Van Meir EG, Wilkinson KD. BRCA1-associated protein-1 is a tumor suppressor that requires deubiquitinating activity and nuclear localization. Cancer Res. 2008;68(17):6953-2. doi:10.1158/0008-5472.CAN-08-0365 . CrossRef
  5. Matsuoka S, Ballif BA, Smogorzewska A, McDonald ER III, Hurov KE, Luo J, Bakalarski CE, Zhao Z, Solimini N, Lerenthal Y, et al. ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage. Science. 2007;316(5828):1160-. doi:10.1126/science.1140321 . CrossRef
  6. Scheuermann JC, de Ayala Alonso AG, Oktaba K, Ly-Hartig N, McGinty RK, Fraterman S, Wilm M, Muir TW, Muller J. Histone H2A deubiquitinase activity of the polycomb repressive complex PR-DUB. Nature. 2010;465(7295):243-. doi:10.1038/nature08966 . CrossRef
  7. Stokes MP, Rush J, Macneill J, Ren JM, Sprott K, Nardone J, Yang V, Beausoleil SA, Gygi SP, Livingstone M, et al. Profiling of UV-induced ATM/ATR signaling pathways. Proc Natl Acad Sci USA. 2007;104(50):19855-0. doi:10.1073/pnas.0707579104 . CrossRef
  8. Harbour JW, Onken MD, Roberson ED, Duan S, Cao L, Worley LA, Council ML, Matatall KA, Helms C, Bowcock AM. Frequent mutation of BAP1 in metastasizing uveal melanomas. Science. 2010;330(6009):1410-. doi:10.1126/science.1194472 . CrossRef
  9. Machida YJ, Machida Y, Vashisht AA, Wohlschlegel JA, Dutta A. The deubiquitinating enzyme BAP1 regulates cell growth via interaction with HCF-1. J Biol Chem. 2009;284(49):34179-8. doi:10.1074/jbc.M109.046755 . CrossRef
  10. Eletr ZM, Wilkinson KD. An emerging model for BAP1′s role in regulating cell cycle progression. Cell Biochem Biophys. 2011;60(1-):3-1. doi:10.1007/s12013-011-9184-6 . CrossRef
  11. Grabsch H, Dattani M, Barker L, Maughan N, Maude K, Hansen O, Gabbert HE, Quirke P, Mueller W. Expression of DNA double-strand break repair proteins ATM and BRCA1 predicts survival in colorectal cancer. Clin Cancer Res. 2006;12(5):1494-00. doi:10.1158/1078-0432.CCR-05-2105 . CrossRef
  12. Dey A, Seshasayee D, Noubade R, French DM, Liu J, Chaurushiya MS, Kirkpatrick DS, Pham VC, Lill JR, Bakalarski CE, et al. Loss of the tumor suppressor BAP1 causes myeloid transformation. Science. 2012;337(6101):1541-. doi:10.1126/science.1221711 . CrossRef
  13. Jensen DE, Proctor M, Marquis ST, Gardner HP, Ha SI, Chodosh LA, Ishov AM, Tommerup N, Vissing H, Sekido Y, et al. BAP1: a novel ubiquitin hydrolase which binds to the BRCA1 RING finger and enhances BRCA1-mediated cell growth suppression. Oncogene. 1998;16(9):1097-12. CrossRef
  14. Jensen DE, Rauscher FJ 3rd. Defining biochemical functions for the BRCA1 tumor suppressor protein: analysis of the BRCA1 binding protein BAP1. Cancer Lett. 1999;143(Suppl 1):S13-. CrossRef
  15. Nishikawa H, Wu W, Koike A, Kojima R, Gomi H, Fukuda M, Ohta T. BRCA1-associated protein 1 interferes with BRCA1/BARD1 RING heterodimer activity. Cancer Res. 2009;69(1):111-. doi:10.1158/0008-5472.CAN-08-3355 . CrossRef
  16. Pena-Llopis S, Vega-Rubin-de-Celis S, Liao A, Leng N, Pavia-Jimenez A, Wang S, Yamasaki T, Zhrebker L, Sivanand S, Spence P, et al. BAP1 loss defines a new class of renal cell carcinoma. Nat Genet. 2012;44(7):751-. doi:10.1038/ng.2323 . CrossRef
  17. Tang QL, Xie XB, Wang J, Chen Q, Han AJ, Zou CY, Yin JQ, Liu DW, Liang Y, Zhao ZQ, et al. Glycogen synthase kinase-3beta, NF-kappaB signaling, and tumorigenesis of human osteosarcoma. J Natl Cancer Inst. 2012;104(10):749-3. doi:10.1093/jnci/djs210 . CrossRef
  18. Xu S, Feng Z, Zhang M, Wu Y, Sang Y, Xu H, Lv X, Hu K, Cao J, Zhang R, et al. hSSB1 binds and protects p21 from ubiquitin-mediated degradation and positively correlates with p21 in human hepatocellular carcinomas. Oncogene. 2011;30(19):2219-9. doi:10.1038/onc.2010.596 . CrossRef
  19. Kang T, Wei Y, Honaker Y, Yamaguchi H, Appella E, Hung MC, Piwnica-Worms H. GSK-3 beta targets Cdc25A for ubiquitin-mediated proteolysis, and GSK-3 beta inactivation correlates with Cdc25A overproduction in human cancers. Cancer Cell. 2008;13(1):36-7. doi:10.1016/j.ccr.2007.12.002 . CrossRef
  20. Hong J, Hu K, Yuan Y, Sang Y, Bu Q, Chen G, Yang L, Li B, Huang P, Chen D, et al. CHK1 targets spleen tyrosine kinase (L) for proteolysis in hepatocellular carcinoma. J Clin Investig. 2012;122(6):2165-5. doi:10.1172/JCI61380 . CrossRef
  21. Xu S, Wu Y, Chen Q, Cao J, Hu K, Tang J, Sang Y, Lai F, Wang L, Zhang R, et al. hSSB1 regulates both the stability and the transcriptional activity of p53. Cell Res. 2012;. doi:10.1038/cr.2012.162 .
  22. Bott M, Brevet M, Taylor BS, Shimizu S, Ito T, Wang L, Creaney J, Lake RA, Zakowski MF, Reva B, et al. The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma. Nat Genet. 2011;43(7):668-2. doi:10.1038/ng.855 . CrossRef
  23. Testa JR, Cheung M, Pei J, Below JE, Tan Y, Sementino E, Cox NJ, Dogan AU, Pass HI, Trusa S, et al. Germline BAP1 mutations predispose to malignant mesothelioma. Nat Genet. 2011;43(10):1022-. doi:10.1038/ng.912 . CrossRef
  24. Wiesner T, Obenauf AC, Murali R, Fried I, Griewank KG, Ulz P, Windpassinger C, Wackernagel W, Loy S, Wolf I, et al. Germline mutations in BAP1 predispose to melanocytic tumors. Nat Genet. 2011;43(10):1018-1. doi:10.1038/ng.910 . CrossRef
  25. Kapur P, Pena-Llopis S, Christie A, Zhrebker L, Pavia-Jimenez A, Rathmell WK, Xie XJ, Brugarolas J. Effects on survival of BAP1 and PBRM1 mutations in sporadic clear-cell renal-cell carcinoma: a retrospective analysis with independent validation. Lancet Oncol. 2013;14(2):159-7. doi:10.1016/S1470-2045(12)70584-3 . CrossRef
  26. Fan LH, Tang LN, Yue L, Yang Y, Gao ZL, Shen Z. BAP1 is a good prognostic factor in advanced non-small cell lung cancer. Clin Invest Med. 2012;35(4):E182-.
  27. Wright FC, Law CH, Berry S, Smith AJ. Clinically important aspects of lymph node assessment in colon cancer. J Surg Oncol. 2009;99(4):248-5. doi:10.1002/jso.21226 . CrossRef
  28. Royston D, Jackson DG. Mechanisms of lymphatic metastasis in human colorectal adenocarcinoma. J Pathol. 2009;217(5):608-9. doi:10.1002/path.2517 . CrossRef
  
• 作者单位：Jianjun Tang (1)
  Shaoyan Xi (2)
  Gang Wang (1)
  Boqing Wang (1) (4)
  Shumei Yan (2)
  Yuanzhong Wu (1)
  Yi Sang (1)
  Wenjing Wu (1) (3)
  Ruhua Zhang (1)
  Tiebang Kang (1)
  
  1. State Key Laboratory of Oncology in South China, Sun Yat-Sen University Cancer Center, No 651, Dongfeng Road East, Guangzhou, 510060, China
  2. Department of Pathology, Sun Yat-Sen University Cancer Center, Guangzhou, 510060, China
  4. Department of Hepatobiliarypancreatic Surgery, Affiliated Tumor Hospital, Xinjiang Medical University, Urumqi, 830000, China
  3. Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, 510060, China
  

文摘

Mutations of BRCA1-associated protein 1 (BAP1), a nuclear-localized deubiquitinating enzyme, had been documented in multiple human cancers. However, its role and clinical relevance in colorectal cancer is unknown. The purpose of this study was to reveal the prognostic significance of BAP1 in colorectal cancer. We performed quantitative PCR and Western blotting analyses to examine BAP1 expression in 8 cases of CRC tissues and matched adjacent non-cancerous tissues. And immunohistochemistry was used to evaluate BAP1 expression in archived 252 paraffin-embedded CRC specimens. We found that the mRNA and protein levels of BAP1 were down-regulated in 6 out of 8 cases of CRC tissues compared with their adjacent non-cancerous tissues. The BAP1 expression was closely correlated with age (p?=?0.037), clinical stage (p?=?0.001), T classification (p?<?0.001), N classification (p?<?0.001), and pathologic differentiation (p?=?0.008) and histological type (p?=?0.047) in CRC. The CRC patients with lower BAP1 expression survived shorter than those with higher BAP1 expression. Importantly, multivariate analysis demonstrated that BAP1 expression was an independent prognostic factor for CRC (p?=?0.037). Collectively, we provide the first evidence that reduced BAP1 expression is associated with poor prognosis of CRC and BAP1 may serve as a novel prognostic biomarker for CRC.